5-substituted indazoles as kinase inhibitors

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibitin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	PENNING THOMAS D, BAKKER MARGARETHA, LI BIQIN, MACK HELMUT, KALVIN DOUGLAS M, GRACIAS VIJAYA J, HOBSON ADRIAN D, TEUSCH NICOLE, GASIECKI ALAN F, SHUAI QI, VASUDEVAN ANIL, SARRIS KATHY A, GEORGE DAWN, MOORE N. ST. JOHN, PATEL JYOTI R, JOHNSON ERIC F, AKRITOPOULOU-ZANZE IRINI, LONG ANDREW J, WOODS KEITH W, WAKEFIELD BRIAN D, TURNER SEAN C, WANG LU, SWANN, JR. STEVEN L, MICHMERHUIZEN MELISSA J, MIYASHIRO JULIE M, KOVAR PETER J, DJURIC STEVAN W
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.